Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoi
Neoadjuvant immunochemotherapy is safe and effective for locally advanced ESCC, and can result in certain survival benefits. MPR can serve as a surrogate endpoint for predicting long-term OS.
Authors
- Linhai Zhu (ORCID: https://orcid.org/0000-0002-0433-5348)
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Jian Hu
- Ziheng Wu (ORCID: https://orcid.org/0009-0001-0898-8493)
- Pinghui Xia
- Yiqing Wang (ORCID: https://orcid.org/0000-0003-1984-1777)
- Shihong Zhou
- Jia-Cong Liu
Institutions
- Second Affiliated Hospital of Zhejiang University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s40001-025-02599-z
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China